The Association of TSLP and IL-4 with Patient-Reported Outcome Measures in Chronic Rhinosinusitis with Nasal Polyps.

Background: Thymic stromal lymphopoietin (TSLP) plays an important role in mediating the type-2-inflammatory response. This study examined how TSLP and interleukin (IL)-4 levels in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) correlated with clinical and postoperative outcomes.

Methods: Solid-phase sandwich ELISA was used to analyze TSLP and IL-4 levels in mucus (n = 47), plasma (n = 17), polyp (n = 30), inferior (n = 25), and middle (n = 26) turbinate tissue collected during functional endoscopic sinus surgery (FESS) in CRSwNP patients (n = 76) and controls (n = 11).

Biomarkers.

Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder that has impacted millions of people worldwide. Identifying different risk groups converting to AD during the mild cognitive impairment (MCI) stage and determining their genetic basis would be immensely valuable for drug discovery and subsequent clinical treatment. Previous studies typically clustered subgroups by unsupervised learning techniques, neglecting the survival information.

Developing Topics.

Background: Sabirnetug (ACU193) is a humanized monoclonal antibody targeting soluble amyloid beta (Aβ) oligomers, which are early contributors to the pathogenesis of Alzheimer's Disease (AD). An ultrasensitive assay was developed to measure sabirnetug pharmacokinetics (PK) in CSF of individuals with early AD in the Phase 1 study INTERCEPT-AD (NCT04931459).

Method: The immunoassay was developed on the Meso Scale Diagnostics (MSD) S-PLEX with improved sensitivity through TURBO-TAG® technology.

Developing Topics.

Background: The amyloid-tau-neurodegeneration (ATN) framework provides a valuable model for comprehending the pathophysiology and progression of Alzheimer's disease (AD). However the relationship between and genetic interaction with these three characteristics are complex and not fully understood. Here, we use neuroimaging-derived quantitative traits to evaluate the genetic risk for amyloid accumulation, tau pathology, and neurodegeneration.

Conjugation with S4 protein transduction domain enhances the immunogenicity of the peptide vaccine against breast cancer.

Although peptide vaccines offer a novel venue for cancer immunotherapy, clinical success has been rather limited. Cell-penetrating peptides, due to their ability to translocate through the cell membrane, could be conjugated to the peptide vaccine to2 enhance therapeutic efficiency. The S4 transduction domain of the shaker-potassium channel was conjugated to mammaglobin-A (MamA) immunodominant epitope (MamA2.